Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: A systematic review

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 2, 2006, Pages 253-263

  Di Trolio, R ^a   Di Lorenzo, Giuseppe ^b   Delfino, M ^b   De Placido, S ^a  

^a Dipartimento di Patologia Sistematica Clinica Dermatologica

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemotherapy; Kaposi's sarcoma; Pegylated liposomal doxorubicin

Indexed keywords

ABACAVIR; ALITRETINOIN; ANTHRACYCLINE; BLEOMYCIN; CORTICOSTEROID; DAUNORUBICIN; DOXORUBICIN; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; LIVER ENZYME; MACROGOL; PROTEINASE INHIBITOR; RETINOL DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINBLASTINE; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANEMIA; APOPTOSIS; BODY SURFACE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CRYOTHERAPY; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG INHIBITION; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; ENCAPSULATION; FEVER; GENETIC PREDISPOSITION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART DEATH; HEART FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LOW LEVEL LASER THERAPY; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; REVIEW; SKIN CANCER; SKIN IRRITATION; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; TREATMENT FAILURE; TUMOR; TUMOR GROWTH;

EID: 33746825454     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200601900202     Document Type: Review

References (44)

1. Krown S.E. 1998. Clinical overview: issues in Kaposi's sarcoma therapeutics. J. Natl. Cancer Inst. Monogr. 23:59.
2. Mitsuyasu R.T. 2000. AIDS-related Kaposi's sarcoma: Current treatment options, future trends. Oncology 14:867.
3. Krown S.E. 2004. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: Implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J. Clin. Oncol. 22:399.
4. Wang C.Y., A.L. Schroeter and W.P. Su. 1995. Acquired immunodeficiency syndrome-related Kaposi's sarcoma. Mayo Clin. Proc. 70:869.
5. Masala M. V., C. Cercassi, F. Cottoni, M. Mulargia, L. Contu and D. Cerimele. 2005. Classic Kaposi's sarcoma in Sardinia: HLA positive and negative associations. Int. J. Dermatol. 44:743.
6. Iscovich J., P. Bolletta, S. Franceschi, E. Azizi and R. Sarid. 2000. Classic Kaposi sarcoma: Epidemiology and risk factors. Cancer 88:500.
7. Weiss R.A., D. Whitby, S. Talbot, P. Kellam and C. Boshoff. 1998. Classic Kaposi sarcoma-associated herpesvirus. J. Natl. Cancer Inst. Monogr. 23:51.
8. Walmsley S., D.W. Northfelt, B. Melosky, M. Conant, A.E. Friedman-Kien and B. Wagner. 1999. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin gel. J. Acquir. Immune Defic. Syndr. 22:235.
9. Duvic M., A.E. Friedman-Kien, D.J. Looney, et al. 2000. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: Results of phase 1 and 2 trials. Arch. Dermatol. 136:1461.
10. Volberding P.A., D.I. Abrams, M. Conant, K. Kaslow, K. Vranizan and J. Ziegler. 1985. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann. Intern. Med. 101:876.
11. Fischl M.A., S.E. Krown, K.P. O'Boyle, R. Mitsuyasu, S. Miles, J.C. Wernz, P.A. Volberding, J. Kahn, J.E. Groopman and J. Feinberg. 1993. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS. Clinical Trials Group. J. Acquir. Immune Defic. Syndr. 6:259.
12. Hernandez D.E. and J.R. Perez. 1996. Advanced epidemic Kaposi's sarcoma: Treatment with bleomycin or combination of doxorubicin, bleomycin and vincristine. Int. J. Dermatol. 35:831.
13. Gill P.S., M. Rarich, J.A. McCutchan, L. Slater, B. Parker, E. Muchmore, M. Bernstein-Singer, B. Akil, B.M. Espina and M. Krailo. 1991. Systemic treatment of AIDS-related Kaposi's sarcoma. Results of a randomized trial. Am. J. Med. 90:427.
14. Doxil. Doxorubicin HCl liposome injection, prescribing information. 2001. Bridgwater NJ Ortho. Biotech. Products LP, p. 1.
15. Cheung T.W., S.C. Remich and N. Azarnia. 1999. AIDS-related Kaposi's sarcoma: A phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin. Cancer Res. 5:3432.
16. Allen T.M. and F.J. Martin. 2004. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. (S) 31:5.
17. Logan D.M., L.G. Filion and R. Gaudreault. 1991. The effect of daunorubicin or doxorubicin on epidemic Kaposi's sarcoma (EKS)-derived cell cultures. Int. Conf. AIDS 7:99.
18. Sturzl M., C. Zietz and B. Eisenburg. 1994. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: Clinical, histological and cell biological evaluation. Res. Virol. 145:261.
19. Huang S.K., F.J. Martin and G. Jay. 1993. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. 143:10.
20. Vogel J., S.H. Hinrichs, R.K. Reynolds and P.A. Luciw. 1988. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 335:606.
21. Vail D.M., M.A. Amantea and G.T. Colbern. 2004. Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. (S) 31:16.
22. Hengge U.R., N.H. Brockmeyer and M. Baumann. 1993. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 342:497.
23. Simpson J.K., R.F. Miller and M.F. Spittle. 1993. Liposomal doxorubicin in AIDS-related Kaposi sarcoma. Clin. Oncol. 5:372.
24. Bogner J.R., U. Kronawitter and B. Rolinski. 1994. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 7:463.
25. James N.D., R.J. Coker and D. Tomlinson. 1994. Liposomal doxorubicin: an effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol. 6:294.
26. Wagner D., W.V. Kern and P. Kern. 1994. Liposomal doxorubicin in AIDS related Kaposi's sarcoma: long-term experiences. Clin. Investig. 72:417.
27. Bergin C., A. O'Leary and C. McCreary. 1995. Treatment of Kaposi's sarcoma with liposomal doxorubicin. Am. J. Health Syst. Pharm. 52:2001.
28. Harrison M., D. Tomlinson and S. Stewart 1995. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 13:914.
29. Goebel F.D., D. Goldstein and M. Goos. 1996. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br. J. Cancer 73:989.
30. Northfelt D.W., B.J. Dezube and J.A. Thommes. 1997. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 15:653.
31. Grunaug M., J.R. Bogner and O. Loch. 1998. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: Improved survival as compared to patients without liposomal doxorubicin. Eur. J. Med. Res. 3:13.
32. Newell M., S. Milliken and D. Goldstein. 1998. A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi sarcoma. Aust. N.Z. J. Med. 28:777.
33. Hengge U.R., S. Esser and H.P. Rudel. 2001. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur. J. Cancer 37:878.
34. Nunez M., P. Saballs and M.E. Valencia. 2001. Response to liposomal doxorubicin and clinical outcome of HIV-1 infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin. Trials 2:429.
35. Northfelt D.W., B.J. Dezube and J.A. Thommes. 1998. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine treatment of AIDS-related Kaposi's sarcoma. Results of a randomized phase III clinical trial. J. Clin. Oncol. 16:2445.
36. Stewart S.H., N. Jablonowski and F.D. Goebel. 1998. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J. Clin. Oncol. 16:683.
37. Osoba D., D.W. Northfelt and D.W. Budd. 2001. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma. A randomized trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine. Cancer Invest. 19:573.
38. Henry D.T., P. Cooley and P.A. Volberding. 2002. Final results of a phase III randomized trial of Doxil vs DaunoXome in patients with AIDS-related Kaposi's sarcoma (KS). Proc. Am. Soc. Clin. Oncol. 21:41.
39. Mitsuyasu R.T., J. Von Roenn and S. Krown. 1997. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) in the treatment of advanced AIDS Clinical Trial Group (ACTG) protocol 286. Proc. Am. Soc. Clin. Oncol. 16:55.
40. Martin-Cabernero L., A. Barrios, P. Saballs, G. Sirera, J. Santos, R. Palacios, M.E. Valencia, M. Alegre, D. Podzamczer and J. Gozalez-Lahoz. 2004. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18:1737.
41. Lichterfeld M., C. Quirishi, C. Hoffmann, B. Hochdorfer, N.H. Brockmeyer, K. Arasteh, S. Mauss and J.K. Rocksrtoh. 2005. Treatment of HIV-1 - associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T Cell recovery. Infection 33:140.
42. Bossini N., S. Mandrini, G. Setti, M. Luppi, P. Maiorca, C. Maffei and G. Concarini. 2005. Successful treatment with liposomal doxorubicin and foscarnet in a patient with widespread Kaposi's sarcoma and human herpes virus 8-related, serious hemophagocytic sindrome, after renal transplantation. G. Ital. Nefrol. 22:281.
43. Fracasso P.M., K.A. Blum, M.K. Ma, B.R. Tan, L.P. Wright, S.A. Goodner, C.L. Fears, Hou, M.A. Arquette, J. Picus, A. Denes, J.E. Mortimer, L. Ratner and H.L. McLeod. 2005. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br. J. Cancer 93:46.
44. Little R.F., K.M. Wyvill, J.M. Pluda, L. Welles, V. Marshall, W.D. Figg, F.M. Newcomb, G. Tosato, E. Feigal, S.M. Steinberg, D. Whitby, J.J. Goedert and R. Yarchoan. 2000. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 18:2593.